ArticlePloS one2014
On the reproducibility of TCGA ovarian cancer microRNA profiles.
Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Exosomal microRNAs in cancer: Potential biomarkers and immunotherapeutic targets for immune checkpoint molecules.Frontiers in genetics · 2023Review
- High heterogeneity undermines generalization of differential expression results in RNA-Seq analysis.Human genomics · 2021Article
- Inhibition of miR-141 and miR-200a IncreaseInternational journal of environmental research and public health · 2020Article
- Apparent bias toward long gene misregulation in MeCP2 syndromes disappears after controlling for baseline variations.Nature communications · 2018Article
- Identification of a gene expression signature predicting survival in oral cavity squamous cell carcinoma using Monte Carlo cross validation.Oral oncology · 2018Article
- The expression of miRNAs is associated with tumour genome instability and predicts the outcome of ovarian cancer patients treated with platinum agents.Scientific reports · 2017Article
- The role of MicroRNA molecules and MicroRNA-regulating machinery in the pathogenesis and progression of epithelial ovarian cancer.Gynecologic oncology · 2017Review
- Downregulation of Foxo3 and TRIM31 by miR-551b in side population promotes cell proliferation, invasion, and drug resistance of ovarian cancer.Medical oncology (Northwood, London, England) · 2016Article
- Loss of MeCP2 in the rat models regression, impaired sociability and transcriptional deficits of Rett syndrome.Human molecular genetics · 2016Article
- Roles of the canonical myomiRs miR-1, -133 and -206 in cell development and disease.World journal of biological chemistry · 2015Review
- The Landscape of long noncoding RNA classification.Trends in genetics : TIG · 2015Review
- Article
- Integrated analysis reveals microRNA networks coordinately expressed with key proteins in breast cancer.Genome medicine · 2015Article
- Distinct microRNA expression profiles in mouse renal cortical tissue after 177Lu-octreotate administration.PloS one · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dysregulated microRNA (miRNA) expression is a well-established feature of human cancer. However, the role of specific miRNAs in determining cancer outcomes remains unclear. Using Level 3 expression data from the Cancer Genome Atlas (TCGA), we identified 61 miRNAs that are associated with overall survival in 469 ovarian cancers profiled by microarray (p<0.01). We also identified 12 miRNAs that are associated with survival when miRNAs were profiled in the same specimens using Next Generation Sequencing (miRNA-Seq) (p<0.01). Surprisingly, only 1 miRNA transcript is associated with ovarian cancer survival in both datasets. Our analyses indicate that this discrepancy is due to the fact that miRNA levels reported by the two platforms correlate poorly, even after correcting for potential issues inherent to signal detection algorithms. Corrections for false discovery and microRNA abundance had minimal impact on this discrepancy. Further investigation is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.